Senti Biosciences
South San Francisco
About Senti Biosciences
Senti Biosciences is a biotechnology company focused on synthetic biology and gene circuit engineering for therapeutic applications. Senti Bio utilizes a synthetic biology platform named Gene Circuits to develop therapies that offer improved precision and control. These circuits are engineered to selectively eliminate cancer cells while sparing healthy ones, enhancing specificity for target cells, and regulating drug expression post-administration. Senti's Gene Circuits have been demonstrated in preclinical studies to be effective in both NK and T cells. Additionally, Senti Bio has shown in preclinical research the potential applicability of Gene Circuits in a variety of other treatment areas and diseases beyond oncology, and is actively progressing these efforts through partnerships.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $272.5M
- Funding stage: IPO
- Last round: Grant (May 2025)
- Ticker: nasdaq:SNTI
- Website: sentibio.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/senti-biosciences-35557 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.